1. Home
  2. Labeler Index
  3. Aphena Pharma Solutions - Tennessee, Llc
  4. 71610-401
  5. Product Images: Duloxetine

Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Duloxetine NDC 71610-401 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 20 mg - 71610 0401 83

Bottle Label 20 mg - 71610 0401 83

This is a product description for Duloxetine DR, USP, which is a medication available in 20mg dose and comes in a package of 3600 capsules. The NOC number is also provided.*

Bottle Label 30 mg - 71610 0402 60

Bottle Label 30 mg - 71610 0402 60

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

This is a figure showing the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a MDD Study 5. It includes a graph with time on the x-axis and the proportion of patients with relapse on the y-axis. The two treatments, placebo and duloxetine, are represented by two lines.*

fig2 - duloxetine fig2

fig2 - duloxetine fig2

Figure 3: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-1 - duloxetine fig3

Figure 3: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-1 - duloxetine fig3

Figure 4: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2 - duloxetine fig4

Figure 4: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2 - duloxetine fig4

Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1 - duloxetine fig5

Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1 - duloxetine fig5

Figure 8: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3 - duloxetine fig6

Figure 8: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3 - duloxetine fig6

Figure 9: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1 - duloxetine fig7

Figure 9: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1 - duloxetine fig7

This appears to be a graph or chart related to the effectiveness of a medication called Duloxetine in reducing pain levels versus a placebo. The graph shows the percentage of patients who achieved varying levels of pain relief based on a baseline measurement. Unfortunately, without more context or information it is difficult to provide a more detailed description or analysis.*

Structure - duloxetine str

Structure - duloxetine str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.